Gongxin He, PhD

Biography

Dr. Gongxin He is a distinguished pharmaceutical scientist and entrepreneur with a career spanning over three decades in innovative drug research and development. He earned his PhD in Synthetic Chemistry from Kyushu University (Japan) in 1988 and conducted his postdoctoral research at the University of California, Santa Barbara.
Dr. He's most notable contribution came during his career at Gilead Sciences (1992-2018), where he was the principal inventor and project leader for tenofovir alafenamide (TAF). TAF has become the cornerstone of multiple blockbuster HIV regimens (e.g., Genvoya® and Biktarvy®) and the leading therapy for chronic hepatitis B (Vemlidy®). From 2008 to 2018, as the Chief Representative and General Manager of Gilead Sciences China affiliate, Dr, He established and managed Gilead end-to-end supply chain in China, overseeing over 150 CROs/CMOs.
In 2018, Dr. He founded CureGene Pharmaceutical, where he leads the development of a batch of promising pipelines, including CG-0255, a next-generation antiplatelet drug under global clinical development; CG-0985, a broad-spectrum antiviral drug showing high antiviral activities against many common respiratory RNA viruses, and CG-1999, a novel mRNA-based immune modulator with the potential for a functional cure for HBV.